2nd World Immunotherapy Council Young Investigator Symposium Schedule

As a benefit for attending the 32nd Annual Meeting and Pre-Conference Programs, SITC provides enduring materials free of charge for the specific programs attended. If you are a SITC member, or member of the general public, but did not register to attend a Pre-Conference program or the 32nd Annual Meeting, the materials are available for purchase by clicking here.

Presentations and video recordings are available based on permission from presenters.

no_symbol.png  Presentations with this symbol indicate that the presenter did not grant permission to the presentation. 


Wednesday, Nov. 8
1 – 1:05 p.m. Welcome & Introductions
Tanja de Gruijl, PhD – VU University Medical Center
Graham Pawelec, PhD – University of Tuebingen		 Cherry Blossom Ballroom

Session I: Checkpoint Blockade
Senior Co-Chairs:

Beatrix Kotlan, PhD – National Institute of Oncology, Budapest
Sacha Gnjatic, PhD – Cancer Research Institute (CRI)
Zihai Li, MD, PhD – Chinese American Hematology Oncology Network (CAHON)
Lisa H. Butterfield – Society for Immunotherapy of Cancer (SITC)
Willemijn Hobo, PhD – Dutch Tumor Immunology Working Party (DTIWP)
1:05 – 1:10 p.m. Welcome & Introductions
Junior Co-Chair: Hong Zheng, MD, PhD – Pennsylvania State Cancer Institute
1:10 – 1:25 p.m. Immunotherapy - Long Term Survival Metastic Melanoma
Katalin Czirbesz, MD – National Institute of Oncology, Budapest
1:25 – 1:40 p.m. PD-1 Blockade: Understanding CD8 T Cell Rescue for Insights into Cancer Immunotherapy
Alice O. Kamphorst, PhD – Cancer Research Institute (CRI)
1:40 – 1:55 p.m. Viral-based Cancer Immunotherapy in the Era of Immune Checkpoint Blockade
Liang Deng, MD, PhD – Chinese American Hematology Oncology Network (CAHON)
1:55 – 2:10 p.m. Treg Modulation as a Pharmacodynamicno_symbol.png Biomarker of GITR Stimulation in Cancer Patients
Roberta Zappasodi, PhD – Society for Immunotherapy of Cancer (SITC)
2:10 – 2:25 p.m. PD-L1 Expression on Malignant Cells is no Prerequisite for Checkpoint Therapy
Jan Willem Kleinovink, PhD – Dutch Tumor Immunology Working Party (DTIWP)
2:25 – 2:40 p.m. Break

Session II: Adoptive T cell Therapy
Senior Co-Chairs:

Robert E. Hawkins, MD, PhD – Adoptive Engineered T Cell Targeting to Activate Cancer Killing (ATTACK)
Per thor Straten, PhD – Progress in Vaccination Against Cancer (PIVAC)
Pamela Ohashi, PhD – Canadian Cancer Immunotherapy Consortium (CCIC)
2:40 – 2:45 p.m. Welcome & Introductions
Junior Co-Chair: Marco Ruella, MD – University of Pennsylvania
2:45 – 3:00 p.m. Exploiting Tumor Infiltrating Lymphocytes no_symbol.png(Tils) as a Therapeutic Strategy for Epithelial Ovarian Cancer
Gemma Owens, MB, BCh – Adoptive Engineered T Cell Targeting to Activate Cancer Killing (ATTACK)
3:00 – 3:15 p.m. Combined Killing of Cancer Cells and Crossno_symbol.png Presentation of Tumor Antigen By Vγ9Vδ2 T Cells
Gitte Holmen Olofsson, MS – Progress in Vaccination Against Cancer (PIVAC)
3:15 – 3:30 p.m. A Novel Innate Lymphoid Cell Population no_symbol.pngRegulates Tumor-Associated T Cells
Sarah Crome, PhD – Canadian Cancer Immunotherapy Consortium (CCIC)
3:30 – 3:45 p.m. Break

Session III: Innate Immunity
Senior Co-Chairs:

Weihua Xiao, MD, MS – Chinese Society of Immunology (CSI) and Committee for Tumor Immunology and Bio-Therapy (TIBT)
Heinz Zwierzina, MD – Cancer Drug Development Forum (CDDF)
Angus Dalgleish, MD, PhD – Institute for Cancer Vaccines and Immunotherapy (ICVI)
3:45 – 3:50 p.m. Welcome & Introductions
Junior Co-Chair: Cheng Sun, MD, PhD – Chinese Academy of Sciences and University of Science and Technology of China
3:50 – 4:05 p.m. Dysfunction of Dendritic Cells in Lung Cancer
Fang Fang, PhD – Chinese Society of Immunology (CSI) and Committee for Tumor Immunology and Bio-Therapy (TIBT)
4:05 – 4:20 p.m. Development of a Novel Immunotherapy with Toll-Like and Nod-Like Receptors Synergy for Targeted Cancer Therapyno_symbol.png
Celia Jacoberger-Foissac, MSc – Cancer Drug Development Forum (CDDF)
4:20 – 4:35 p.m. Zoledronic Acid Induces Gamma Delta T Cells to Target Macrophages
Daniel William Fowler, PhD – Institute for Cancer Vaccines and Immunotherapy (ICVI)
4:35 – 5:40 p.m. Dinner

Session IV: Novel Approaches to Improve Immunotherapy
Senior Co-Chairs:

Kazuhiro Kakimi, MD, PhD – Japanese Association of Cancer Immunotherapy (JACI)
Barbara Seliger, MD, PhD – Tumor Immunology Meets Oncology (TIMO)
Michele Maio, MD, PhD – NIBIT Foundation (Network Italiano per la Bioterapia dei Tumori)
Giuseppe Masucci, MD, PhD – Scandinavian Network for Immunotherapy of Cancer (SNIC)
5:40 – 5:45 p.m. Welcome & Introductions
Junior Co-Chair: Margot Pont, PhD – Fred Hutchinson Cancer Research Center
5:45 – 6 p.m. An Immunogram for the Cancer-Immunity Cycle: Towards Personalized Cancer Immunotherapy
Takahiro Karasaki, MD – Japanese Association of Cancer Immunology (JACI)
6 – 6:15 p.m.

Reversing the Tumor Immune Escape with Selenium
Claudia Lennicke, PhD – Tumor Immunology Meets Oncology (TIMO)

6:15 – 6:30 p.m.

Epigenetic Immunomodelling to Improve the Efficacy of Cancer Immunotherapy
Alessia Covre, PhD – NIBIT Foundation (Network Italiano per la Bioterapia dei Tumori)

6:30 – 6:45 p.m.

Blood in Circulation, with Intact Cascade Systems, as a Tool to Predict First - Infusion Reactions and Mechanism of - Action of Immunotherapeuticsno_symbol.png
Erika Fletcher, PhD – Scandinavian Network for Immunotherapy of Cancer (SNIC)

6:45 – 7 p.m.

Closing Remarks
Graham Pawelec, PhD – University of Tuebingen